Pfizer Inc. (NYSE:PFE) Shares Sold by Generali Investments CEE investicni spolecnost a.s.

Generali Investments CEE investicni spolecnost a.s. trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 32.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,950 shares of the biopharmaceutical company's stock after selling 30,200 shares during the period. Generali Investments CEE investicni spolecnost a.s.'s holdings in Pfizer were worth $1,570,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Beam Wealth Advisors Inc. lifted its holdings in Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after purchasing an additional 401 shares in the last quarter. Providence Capital Advisors LLC lifted its holdings in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock worth $3,034,000 after acquiring an additional 409 shares during the period. Donaldson Capital Management LLC lifted its holdings in shares of Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after acquiring an additional 410 shares during the period. William B. Walkup & Associates Inc. lifted its holdings in shares of Pfizer by 1.2% during the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after acquiring an additional 454 shares during the period. Finally, Balboa Wealth Partners lifted its holdings in shares of Pfizer by 1.6% during the 4th quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company's stock worth $814,000 after acquiring an additional 480 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.5%

NYSE:PFE traded up $0.13 during trading hours on Friday, hitting $25.45. The stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,722,894. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The business has a 50 day simple moving average of $23.72 and a two-hundred day simple moving average of $24.81. The company has a market cap of $144.66 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the company earned $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PFE. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. TD Cowen cut their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Finally, BMO Capital Markets cut their price objective on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.